1. Volume 9, Issue 2, Pages 105-116 (February 2008)
Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60) 
Prof Michael Pfreundschuh, MD, Joerg Schubert, MD, Marita Ziepert, Dipl-Math, Rudolf Schmits, MD, Martin Mohren, MD, Eva Lengfelder, MD, Marcel Reiser, MD, Christina Nickenig, MD, Michael Clemens, MD, Norma Peter, MD, Prof Carsten Bokemeyer, MD, Hartmut Eimermacher, MD, Prof Anthony Ho, MD, Martin Hoffmann, MD, Prof Roland Mertelsmann, MD, Prof Lorenz Trümper, MD, Leopold Balleisen, MD, Ruediger Liersch, MD, Bernd Metzner, MD, Frank Hartmann, MD, Bertram Glass, MD, Viola Poeschel, MD, Norbert Schmitz, MD, Prof Christian Ruebe, MD, Prof Alfred C Feller, MD, Prof Markus Loeffler, MD 
The Lancet Oncology 
Volume 9, Issue 2, Pages (February 2008)
DOI: /S (08)
Copyright © 2008 Elsevier Ltd Terms and Conditions

2. Figure 1 Trial profile *On June 14, 2005, when the trial was stopped.
The Lancet Oncology 2008 9, DOI: ( /S (08) )
Copyright © 2008 Elsevier Ltd Terms and Conditions

3. Figure 2
Event-free (A), progression-free (B), and overall (C) survival of 1222 elderly patients with aggressive CD20+ B-cell lymphoma treated in the RICOVER-60 trial
Patients were assigned to six or eight cycles of CHOP-14 with or without eight cycles of rituximab. 1=6×CHOP-14; 2=8×CHOP-14; 3=6×R-CHOP-14; 4=8×R-CHOP-14.
The Lancet Oncology 2008 9, DOI: ( /S (08) )
Copyright © 2008 Elsevier Ltd Terms and Conditions

4. Figure 3
Event-free survival of elderly patients according to International Prognostic Index (IPI) risk group
(A) Low-risk patients (6×CHOP-14: n=98; 8×CHOP-14: n=90; 6×R-CHOP-14: n=94; 8×R-CHOP-14: n=90;). (B) Low-intermediate risk patients (6×CHOP-14: n=80; 8×CHOP-14: n=87; 6×R-CHOP-14: n=89; 8×R-CHOP-14: n=83;). (C) High-intermediate risk patients (6×CHOP-14: n=80; 8×CHOP-14: n=78; 6×R-CHOP-14: n=78; 8×R-CHOP-14: n=77). (D) High-risk patients (6×CHOP-14: n=49; 8×CHOP-14: n=50; 6×R-CHOP-14: n=45; 8×R-CHOP-14: n=54). 1=6×CHOP-14. 2=8×CHOP-14. 3=6×R-CHOP-14. 4=8×R-CHOP-14.
The Lancet Oncology 2008 9, DOI: ( /S (08) )
Copyright © 2008 Elsevier Ltd Terms and Conditions

5. Figure 4 Event-free survival of patients
Patients with complete responses (A), unconfirmed complete responses (B), and partial response (C) after four cycles of CHOP-14 with and without rituximab. 1=6×CHOP-14; 2=8×CHOP-14; 3=6×R-CHOP-14; 4=8×R-CHOP-14. Complete responses (n=261), unconfirmed complete responses (n=276), partial response (n=459).
The Lancet Oncology 2008 9, DOI: ( /S (08) )
Copyright © 2008 Elsevier Ltd Terms and Conditions

6. Figure 5
Total doses of cyclophosphamide, adherence to 14-day schedule, and relative dose intensities of cyclophosphamide in the RICOVER-60 trial
Blue line=6×CHOP-14. Red line=8×CHOP-14. Green line=6×R-CHOP-14. Purple line=8×R-CHOP-14.
The Lancet Oncology 2008 9, DOI: ( /S (08) )
Copyright © 2008 Elsevier Ltd Terms and Conditions